5-ALA Enteric Coating for Local IBD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn's disease, face challenges including high dosing frequency, poor patient compliance, and adverse effects associated with systemic exposure and injections.
Innovation Solution
The use of 5-aminolevulinic acid (5-ALA) delivered topically to the inflamed colon, either through rectal administration or delayed release oral formulations, to reduce inflammatory biomarkers and provide anti-inflammatory effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high dose mesalazine (3-4 g/day) is administered to treat IBD, then therapeutic effect is improved, but patient compliance deteriorates due to high frequency of dosing
Solution Approach 1:
The patent segments the drug delivery system into multiple dosage forms (tablets, capsules, sachets) that can be administered at different frequencies. The enteric-coated formulations are divided into units that release drug at specific intestinal locations, allowing flexible dosing schedules that maintain therapeutic effect while improving compliance.
Solution Approach 2:
The patent employs enteric coating technology that performs preliminary protection of the drug and targeted release mechanism before the drug reaches the intestine. The coating is applied in advance to ensure the drug survives stomach acid and releases at the intended site, eliminating the need for frequent dosing while maintaining therapeutic effect.
2Reliability
If biologics-based treatments are used to target inflammatory cytokines, then anti-inflammatory effect is improved, but adverse effects worsen due to high systemic exposure and frequent injections
Solution Approach 1:
The patent applies local quality by using enteric-coated formulations that deliver 5-ASA specifically to the intestine where IBD occurs. This localized delivery concentrates the therapeutic effect at the disease site while minimizing systemic exposure, thereby reducing adverse effects associated with biologics while maintaining anti-inflammatory efficacy.
Solution Approach 2:
The enteric coating acts as an intermediary that facilitates targeted delivery of 5-ASA to the intestine. This mediator protects the drug from degradation in the stomach and ensures release at the intended site, achieving local therapeutic effect with minimal systemic exposure and reduced adverse effects.
3Ease of operation
If 5-ALA is delivered orally to treat colitis, then systemic absorption occurs, but local anti-inflammatory effect in the colon deteriorates due to metabolism in the small intestine
Solution Approach 1:
The patent applies preliminary action by using enteric coating that protects 5-ALA from metabolism in the small intestine and ensures release in the colon. The coating is prepared in advance to withstand gastric acid and intestinal enzymes, allowing 5-ALA to reach the colon intact and exert local anti-inflammatory effects despite oral administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Topical colonic delivery of 5-ALA achieves superior anti-inflammatory effects compared to oral dosing, with enhanced stability and penetration into colon tissue, reducing key inflammatory biomarkers and improving treatment compliance.
Implementation Method 1
Topical colonic delivery of 5-ALA achieves superior anti-inflammatory effects compared to oral dosing, with enhanced stability and penetration into colon tissue
Data Source
AI summary
The present invention relates to the therapeutic use of compositions containing 5-aminolevulinic acid for the local treatment of inflammatory bowel disease, including but not restricted to ulcerative colitis and Crohn's disease.